Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer
Source check: Source checked. Not independent scientific confirmation.
Finding: The July 25, 2023 Research Square v1 reports ORACLE, an elastic-net score combining clinical factors with serum proteins to stratify time-to-recurrence risk after complete response to chemotherapy for high-grade ovarian cancer. In a discovery cohort of 71 patients, the score separated recurrence outcomes; a prospectively collected independent cohort of 33 patients showed validation TTR HR 4.71 (95% CI 1.75–12.7, p=0.002). The peer-reviewed journal version appeared November 27, 2023 and reports the same study. Validation was single-institution and does not establish clinical utility.
Technology: ORACLE elastic-net risk score
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
- AI contribution
- Elastic net combines age, treatment/surgical factors, stage, CA125 and four serum proteins into the ORACLE score; the score is tuned against survival/TTR.
- Test and result
- ORACLE combined age, treatment/surgical factors, stage, CA125 and serum proteins. The discovery cohort included 71 patients; an independently prospectively collected 33-patient cohort had TTR HR 4.71 (95% CI 1.75–12.7, p=0.002) for the reported risk groups.
- Limitation / still unknown
- The validation cohort was prospectively collected at the same institution; wider external validity and clinical utility remain unestablished.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://assets-eu.researchsquare.com/files/rs-3112324/v1/67b40c92-f203-4ef6-b534-f8184d9ab326.pdf · https://www.nature.com/articles/s41598-023-47983-z
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.